Case of benralizumab‐induced exacerbations of chronic spontaneous urticaria

Eli Magen; Irina Komarova; Israel Magen; Sofia Phirtskhalava

doi:10.1002/ccr3.5930

Clinical Case Reports (Jun 2022)

Case of benralizumab‐induced exacerbations of chronic spontaneous urticaria

Eli Magen,
Irina Komarova,
Israel Magen,
Sofia Phirtskhalava

Affiliations

Eli Magen: Department of Medicine C, Clinical Immunology and Allergy Division Barzilai University Medical Center Ben‐Gurion University of the Negev Ashkelon Israel
Irina Komarova: Department of Medicine C, Clinical Immunology and Allergy Division Barzilai University Medical Center Ben‐Gurion University of the Negev Ashkelon Israel
Israel Magen: Tbilisi State Medical University Tbilisi Georgia
Sofia Phirtskhalava: Tbilisi State Medical University Tbilisi Georgia

DOI: https://doi.org/10.1002/ccr3.5930
Journal volume & issue: Vol. 10, no. 6
pp. n/a – n/a

Abstract

Read online

Abstract The role of IL‐5 in chronic spontaneous urticarial (CSU) is unclear. It may be that benralizumab is an important bidirectional modifier of CSU; that is, blocking IL‐5 may improve CSU in some patients, but it is possible that it may worsen CSU in others.

Published in Clinical Case Reports

ISSN: 2050-0904 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Medicine (General)
Website: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2050-0904

About the journal

Abstract

Keywords